Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 79.00 | |
10 mg | In stock | $ 133.00 | |
25 mg | In stock | $ 233.00 | |
50 mg | In stock | $ 363.00 | |
100 mg | In stock | $ 538.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 88.00 |
Description | JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM). |
Targets&IC50 | CX3CR1:0.32 nM |
Animal Research | SKBR3 human breast cancer cells were serum starved for four hours before being exposed to 50nM recombinant human FKN for 5 minutes, with or without previous incubation with either a CX3CR1 neutralizing antibody used at 15μg/ml or the JMS-17-2 antagonist (10nM) for 30 minutes at 37 ℃. |
Molecular Weight | 419.95 |
Formula | C25H26ClN3O |
CAS No. | 1380392-05-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (26.19 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JMS-17-2 1380392-05-1 Autophagy GPCR/G Protein Immunology/Inflammation CXCR CX3CR1 inhibit GPR13 CX3C chemokine receptor1 fractalkine receptor JMS 17 2 Inhibitor JMS172 inhibitor